临床试验/NCT00859937

NCT00859937已完成2 期

Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors

National Cancer Institute (NCI)34 个研究点分布在 2 个国家目标入组 55 人开始时间: 2009年3月16日最近更新: 2018年4月20日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: National Cancer Institute (NCI)
入组人数: 55
试验地点: 34
主要终点: Progression-free Survival

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This phase II trial is studying how well dasatinib works in treating patients with malignant salivary gland tumors that have come back after treatment or have spread to other parts of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

详细描述

PRIMARY OBJECTIVES:

I. Determine the objective response rate (complete response plus partial response) of dasatinib in adenoid cystic carcinoma (ACC).

II. Determine the progression-free survival of dasatinib in ACC.

SECONDARY OBJECTIVES:

I. Determine the duration of response. II. Determine the stable disease rate and duration of stable disease. III. Determine progression-free survival. IV. Determine the median survival. V. Determine the overall survival. VI. Determine the safety and tolerability.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Histologically or cytologically confirmed malignant salivary gland tumor (MSGT), including one of the following histologic subtypes:
•Adenoid cystic carcinoma (ACC) with c v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (Kit) overexpression or non-ACC MSGT that is not amenable to potentially curable surgery or radiation
•c-KIT overexpression in ACC patients is defined as cluster of differentiation (CD) 117 staining by immunohistochemistry (IHC) in 25% of tumor cells
•No stipulation for c-KIT overexpression is not required for non-ACC MSGT patients
•Patients must have radiographically measurable disease; radiographically measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan
•Patients must have evidence of disease progression (objective growth of existing tumors) within 4 months of study entry
•No known brain metastases, unless patient meets both of the following criteria:
•Neurologic status stable for >= 8 weeks after completion of definitive local therapy (surgery or radiotherapy)
•No neurologic dysfunction that would confound study results
•Life expectancy greater than 12 weeks
•Eastern Cooperative Oncology Group (ECOG) performance status 0-2 OR Karnofsky performance status (PS) >= 60%
•Leukocytes >= 3,000/mcL
•Absolute neutrophil count (ANC) >= 1,500/mcL
•Platelet >= 100,000/mcL
•Hemoglobin >= 9 g/dL
•Serum calcium =< 12.0 mg/dL
•Total serum bilirubin within normal institutional limits
•Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
•Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
•Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; all women of childbearing potential must have a negative pregnancy test prior to receiving dasatinib; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
•Ability to understand and the willingness to sign a written informed consent document

排除标准

•Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; at least 4 weeks must have elapsed since any major surgery
•Patients may not be receiving any other investigational agents
•No prior treatment with any other targeted agents that inhibit vascular endothelial growth factor receptor (VEGFR), Breakpoint cluster region (BCR) ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL), c-Src, c-KIT, platelet-derived growth factor (PDGF) beta receptor, or ephrin type-A receptor 2 (EPHA2) (e.g., imatinib mesylate)
•History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib
•Patients with corrected QT interval (QTc) prolongation (defined as a QTc interval equal to or greater than 500 msec), serious ventricular arrhythmia (ventricular fibrillation or ventricular tachycardia greater than or equal to 3 beats in a row) or other significant echocardiogram (ECG) abnormalities are excluded
•Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication, requirement for intravenous [IV] alimentation, or active peptic ulcer disease) that impairs their ability to swallow and retain dasatinib tablets are excluded
•Patients with any of the following conditions are excluded:
•Serious or non-healing wound, ulcer, or bone fracture
•History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscesses within the past 28 days
•Any history of cerebrovascular accident (CVA) or transient ischemic attack within the past 12 months
•History of myocardial infraction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within the past 6 months
•History of pulmonary embolism within the past 12 months
•Ejection fraction less than institutional normal by echocardiograph (only required for patients with a known history of congestive heart failure, low ejection fraction, or clinical symptoms/findings consistent with congestive heart failure)
•Patients taking medications that are potent inducers or inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) liver enzyme will be determined following a review of their case by the Principal Investigator; every effort should be made to switch patients taking such agents or substances to other medications
•Patients with known brain metastases should be excluded; patients with brain metastases with stable neurologic status following local therapy (surgery or radiation) for at least 8 weeks from definitive therapy and without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events are eligible for participation; patients cannot be receiving enzyme inducing anti-convulsants including carbamazepine, phenobarbital, and phenytoin
•Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infections or psychiatric illness/social situations that would limit compliance with study requirements are ineligible
•Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
•Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
•Patients who have an active pleural or pericardial effusion of any grade
•Diagnosis of any second malignancy within the last 5 years; basal cell carcinoma, squamous cell skin cancer, stage I carcinoma fully treated, or in situ carcinoma that have been adequately treated with no evidence of recurrent disease for 12 months will be eligible

研究组 & 干预措施

Arm I

Experimental

Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

干预措施: Dasatinib (Drug)

Arm I

Experimental

Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

干预措施: Laboratory Biomarker Analysis (Other)

结局指标

主要结局

Progression-free Survival

时间窗: up to 5 years

Progression-free survival from start of treatment to the time of disease progression or death from any cause was estimated using the Kaplan-Meier method.

Response Rate

时间窗: Up to 2 months

Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence. Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.

次要结局

Changes in Laboratory Correlates(Baseline and 4 weeks)
Overall Survival(Up to 5 years)

研究者

发起方

National Cancer Institute (NCI)

申办方类型

Nih

责任方

Sponsor

研究点 (34)

Loading locations...

相似试验

已完成

2 期

NCT00507767National Cancer Institute (NCI)15

已完成

2 期

Dasatinib in Treating Patients With Relapsed Small Cell Lung CancerExtensive Stage Small Cell Lung CancerLimited Stage Small Cell Lung CancerRecurrent Small Cell Lung Cancer

NCT00470054National Cancer Institute (NCI)44

已完成

2 期

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Neoplasm

NCT00423735National Cancer Institute (NCI)64

已完成

2 期

Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal Cancer

NCT00504153National Cancer Institute (NCI)19

已完成

2 期

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast CancerMetastasisBreast Cancer

NCT00371254Bristol-Myers Squibb55